Literature DB >> 16099415

Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells.

Elena K Siapati1, Brian W Bigger, James Miskin, Daniel Chipchase, Kathryn L Parsley, Kyriacos Mitrophanous, Mike Themis, Adrian J Thrasher, Dominique Bonnet.   

Abstract

The use of lentiviral vectors for gene transfer into hematopoietic stem cells has raised considerable interest as these vectors can permanently integrate their genome into quiescent cells. Vectors based on alternative lentiviruses would theoretically be safer than HIV-1-based vectors and could also be used in HIV-positive patients, minimizing the risk of generating replication-competent virus. Here we report the use of third-generation equine infectious anemia virus (EIAV)- and HIV-1-based vectors with minimal viral sequences and absence of accessory proteins. We have compared their efficiency in transducing mouse and human hematopoietic stem cells both in vitro and in vivo to that of a previously documented second-generation HIV-1 vector. The third-generation EIAV- and HIV-based vectors gave comparable levels of transduction and transgene expression in both mouse and human NOD/SCID repopulating cells but were less efficient than the second-generation HIV-1 vector in human HSCs. For the EIAV vector this is possibly a reflection of the lower protein expression levels achieved in human cells, as vector copy number analysis revealed that this vector exhibited a trend to integrate equally efficiently compared to the third-generation HIV-1 vector in both mouse and human HSCs. Interestingly, the presence or absence of Tat in viral preparations did not influence the transduction efficiency of HIV-1 vectors in human HSCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099415     DOI: 10.1016/j.ymthe.2005.01.022

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  12 in total

1.  Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.

Authors:  Alexander Langford-Smith; Fiona L Wilkinson; Kia J Langford-Smith; Rebecca J Holley; Ana Sergijenko; Steven J Howe; William R Bennett; Simon A Jones; Je Wraith; Catherine Lr Merry; Robert F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

2.  Dual transgene expression by foamy virus vectors carrying an endogenous bidirectional promoter.

Authors:  A Andrianaki; E K Siapati; R K Hirata; D W Russell; G Vassilopoulos
Journal:  Gene Ther       Date:  2009-11-12       Impact factor: 5.250

3.  Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation.

Authors:  Fiona L Wilkinson; Ana Sergijenko; Kia J Langford-Smith; Marcela Malinowska; Rob F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

4.  Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.

Authors:  N Naumann; S S De Ravin; U Choi; M Moayeri; N Whiting-Theobald; G F Linton; Y Ikeda; H L Malech
Journal:  Gene Ther       Date:  2007-08-30       Impact factor: 5.250

5.  Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.

Authors:  Qizhen Shi; Erin L Kuether; Yingyu Chen; Jocelyn A Schroeder; Scot A Fahs; Robert R Montgomery
Journal:  Blood       Date:  2013-11-22       Impact factor: 22.113

6.  Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo.

Authors:  Scott Ellis; Liang Fong-Wong; Sharifah Iqball; Vinay Thoree; Kyriacos A Mitrophanous; Katie Binley
Journal:  Mol Ther Nucleic Acids       Date:  2012-12-11       Impact factor: 10.183

7.  Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia.

Authors:  Marina Theodorou; Matthaios Speletas; Antigoni Mamara; Georgia Papachristopoulou; Vassiliki Lazou; Andreas Scorilas; Eleni Katsantoni
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

Review 8.  Foamy virus vectors for HIV gene therapy.

Authors:  Miles E Olszko; Grant D Trobridge
Journal:  Viruses       Date:  2013-10-22       Impact factor: 5.048

9.  In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells.

Authors:  Maria G Roubelakis; Vasiliki Bitsika; Dimitra Zagoura; Ourania Trohatou; Kalliopi I Pappa; Manousos Makridakis; Aristidis Antsaklis; Antonia Vlahou; Nicholas P Anagnou
Journal:  J Cell Mol Med       Date:  2011-09       Impact factor: 5.310

10.  Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease.

Authors:  Ana Sergijenko; Alexander Langford-Smith; Ai Y Liao; Claire E Pickford; John McDermott; Gabriel Nowinski; Kia J Langford-Smith; Catherine L R Merry; Simon A Jones; J Edmond Wraith; Robert F Wynn; Fiona L Wilkinson; Brian W Bigger
Journal:  Mol Ther       Date:  2013-06-07       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.